首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1550638

PARP 抑制剂市场：按药物类型、按应用、按分销管道、按地区

PARP Inhibitor Market, By Drug Type, By Application, By Distribution Channel, By Geography

出版日期: 2024年07月26日 | 出版商:

Coherent Market Insights | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球PARP抑制剂市场规模为72亿美元，预计2031年将达130.2亿美元，2024年至2031年复合年增长率为8.8%。

报告范围		报告详情
基准年	2023年	2024年市场规模	72亿美元
实际资料	2019-2023	预测期	2024年至2031年
预测 2024-2031 年复合年增长率：	8.80%	2031年价值预测	130.2亿美元

图. PARP抑制剂按地区市场占有率（%），2024年

聚（ADP-核糖）聚合酵素（PARP）抑制剂是一种主要用于治疗癌症的标靶治疗。 PARP 抑制剂可透过阻断 PARP 酶（修復受损 DNA）来帮助化疗和放射线治疗更有效地杀死癌细胞。全球 PARP 抑制剂市场的成长是由癌症发病率上升、PARP 抑制剂在癌症治疗中的核准和采用增加所推动的。市面上主要的药物包括奥拉帕尼、尼拉帕尼和鲁卡帕尼，这些药物在治疗乳腺癌、卵巢和前列腺癌方面已被证明有效。随着评估 PARP 抑制剂在新癌症类型和联合治疗中的潜力的研究正在进行，该市场可能会成长。

市场动态：

全球PARP抑制剂市场成长的驱动力是全球癌症发生率的增加以及PARP抑制剂在肿瘤学领域的核准和采用的扩大。根据世界卫生组织统计，2018年，癌症患者人数增加至1,810万人，死亡人数增加至960万人。正在进行的临床试验评估 PARP 抑制剂在更广泛的患者群体中的疗效以及与其他抗癌治疗相结合，可能会推动市场成长。然而，PARP抑制剂的高价格、患者选择时需要进行基因预筛检以及药物核准实施严格的监管途径可能会阻碍市场成长。正在进行的探索新应用和新管道药物的研究可能会在不久的将来为市场成长提供新的机会。

本研究的主要特点

该报告对全球 PARP 抑制剂市场进行了详细分析，并提供了以 2023 年为基准年的预测期（2024-2031 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。它。
它还揭示了各个细分市场的潜在商机，并解释了该市场中有吸引力的投资提案的矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
它包括基于公司亮点、产品系列、主要亮点、财务业绩和策略等参数的全球 PARP 抑制剂市场主要企业的概况。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球 PARP 抑制剂市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过用于分析全球 PARP 抑制剂市场的各种策略矩阵来促进决策。

公司简介
- AstraZeneca
- GlaxoSmithKline
- Merck Co. &Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson &Johnson Services, Inc
- Pfizer Inc.
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.

第10章分析师建议

命运之轮
分析师观点
一致的机会图

第十一章参考文献与调查方法

参考
调查方法

简介目录

Product Code: CMI3037

Global PARP inhibitor market is estimated to be valued at USD 7.20 Bn in 2024 and is expected to reach USD 13.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 7.20 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	8.80%	2031 Value Projection:	US$ 13.02 Bn

Figure. PARP Inhibitor Market Share (%), By Region 2024

Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted therapies used mainly in cancer treatment. These work by blocking the action of PARP enzymes that repair damaged DNA, thus, helping chemotherapy and radiotherapy kill cancer cells more effectively. Global PARP inhibitor market growth is driven by rising cancer incidence, increasing approval and adoption of PARP inhibitors in oncology. Key drugs in the market include Olaparib, Niraparib and Rucaparib which have demonstrated efficacy in treating cancers like breast, ovarian and prostate. With ongoing research evaluating the potential of PARP inhibitors in newer cancer types and combination therapies, the can witness growth.

Market Dynamics:

Global PARP inhibitor market growth is primarily driven by increasing prevalence of cancer worldwide coupled with growing approval and adoption of PARP inhibitors in oncology. According to WHO, cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018. Continuous clinical trials evaluating the efficacy of PARP inhibitors in broader patient segments and combination with other anti-cancer therapies can drive the market growth. However, high cost of PARP inhibitors, requirement of genetic pre-screening for patient selection and imposition of stringent regulatory pathways for drug approval can hamper the market growth. Ongoing research exploring newer applications and emerging pipeline drugs can offer new opportunities for market growth in the near future.

Key Features of the Study:

This report provides in-depth analysis of the global PARP inhibitor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global PARP inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca, Clovis Oncology, TESARO, AbbVie, Pfizer, Merck KGaA
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation-

By Drug Type
- Niraparib
- Olaparib
- Rucaparib
- Talazoparib
- Veliparib
- Others
By Application
- Ovarian Cancer
- Fallopian Tube Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca
- GlaxoSmithKline
- Merck Co. & Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson & Johnson Services, Inc
- Pfizer Inc.
- Repare Therapeutics, Inc.
- Genentech, Inc.
- Artios Pharma
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global PARP Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global PARP Inhibitor Market, By Drug Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Niraparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Olaparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Rucaparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Talazoparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Veliparib
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global PARP Inhibitor Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Ovarian Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Fallopian Tube Cancer
- Mammography
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Breast Cancer
- Chest X-ray
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pancreatic Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global PARP Inhibitor Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global PARP Inhibitor Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- AstraZeneca
  - Company Highlights
  - Method Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GlaxoSmithKline
- Merck Co. & Inc
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson & Johnson Services, Inc
- Pfizer Inc.
- Genentech, Inc.
- Artios Pharma
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- KaryopharmTherapeutics Inc.
- Ono Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

PARP 抑制剂市场：按药物类型、按应用、按分销管道、按地区